NCT05093790View on ClinicalTrials.gov

A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants

PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

March 25, 2022

Primary Completion Date

November 14, 2022

Study Completion Date

November 14, 2022

Conditions
Coronary Artery DiseaseHealthy Participants
Interventions
DRUG

Ticagrelor

Specified dose on specified days

DRUG

BMS-986141

Specified dose on specified days

DRUG

Aspirin

Specified dose on specified days

Trial Locations (1)

EH16 4SA

Local Institution - 0001, Edinburgh

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05093790 - A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants | Biotech Hunter | Biotech Hunter